Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Andrea B, Apolo"'
Autor:
Ninet Sinaii, Guru Sonpavde, Amin H Nassar, Min Yuen Teo, Andrea B Apolo, Jonathan E Rosenberg, Giovanni Maria Iannantuono, Elias B A Chandran, Saad O Atiq, Dilara Akbulut, Nicholas I Simon, Abdul Rouf Banday, Salah Boudjadi, Sandeep Gurram, Gisela Butera, Jonathan A Coleman
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Background Mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) occur in a subset of cancers and have been shown to confer sensitivity to immune checkpoint inhibition (ICI); however, there is a lack of prospective data in uro
Externí odkaz:
https://doaj.org/article/d3920c29bad4423893885de5201f3040
Autor:
Chandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, Yuen San Chan, Danthasinghe Waduge Badrajee Piyarathna, Lacey Elizabeth Dobrolecki, David J. H. Shih, Zhongcheng Shi, Jun Xu, Shixia Huang, Matthew J. Ellis, Andrea B. Apolo, Leomar Y. Ballester, Jianjun Gao, Donna E. Hansel, Yair Lotan, H. Courtney Hodges, Seth P. Lerner, Chad J. Creighton, Arun Sreekumar, W. Jim Zheng, Pavlos Msaouel, Shyam M. Kavuri, Nagireddy Putluri
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract SMARCB1 loss has long been observed in many solid tumors. However, there is a need to elucidate targetable pathways driving growth and metastasis in SMARCB1-deficient tumors. Here, we demonstrate that SMARCB1 deficiency, defined as genomic S
Externí odkaz:
https://doaj.org/article/92dacc4a9b18472087b40b7343faadf4
Autor:
Daniel Castellano, Andrea B. Apolo, Camillo Porta, Jaume Capdevila, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Pablo Maroto
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a syste
Externí odkaz:
https://doaj.org/article/3a9dbb257b134acc968d6ee7d8d17ca9
Autor:
Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Daniel Castellano
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence
Externí odkaz:
https://doaj.org/article/2051059e7aad49d3b982e6644fb0878a
Autor:
Lisa M. Cordes, Nicole N. Davarpanah, Lauren B. Reoma, Billel Gasmi, Martha Quezado, Omar I. Khan, Avindra Nath, Andrea B. Apolo
Publikováno v:
Clinical Case Reports, Vol 8, Iss 1, Pp 24-32 (2020)
Abstract We report a case of nivolumab‐induced delayed‐onset aseptic meningitis and a case of limbic encephalitis and peripheral nerve palsy with toxicity relapse 6 months after initial presentation. The atypical presentations contribute to our k
Externí odkaz:
https://doaj.org/article/0ffa80179e93400d9777ea84b56ff176
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
Autor:
James L Gulley, Sandra P D'Angelo, Marcis Bajars, Andrea B Apolo, Juliane Manitz, S Peter Eggleton, Oliver Bohnsack
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background Patients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead to inappropriate
Externí odkaz:
https://doaj.org/article/c019ed2ada514594b5505a4ffb069dec
Autor:
Cecilia Monge, Hoyoung Maeng, Alessandra Brofferio, Andrea B. Apolo, Bharath Sathya, Andrew E. Arai, James L. Gulley, Marijo Bilusic
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-4 (2018)
Abstract Background Immune checkpoint inhibitors have revolutionized treatment and improved survival in many cancers. However, since immune-related adverse events (irAEs) are potentially fatal, early recognition and prompt treatment are warranted. On
Externí odkaz:
https://doaj.org/article/ae69c4effdae4679acd450ebdfa22fb3
Autor:
Jonathan A. Coleman, Wesley Yip, Nathan C. Wong, Daniel D. Sjoberg, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Eugene K. Cha, Timothy F. Donahue, Eugene J. Pietzak, A. Ari Hakimi, Kwanghee Kim, Hikmat A. Al-Ahmadie, H. Alberto Vargas, Ricardo G. Alvim, Soleen Ghafoor, Nicole E. Benfante, Anoop M. Meraney, Steven J. Shichman, Jeffrey M. Kamradt, Suresh G. Nair, Angelo A. Baccala, Paul Palyca, Bradley W. Lash, Muhammad A. Rizvi, Scott K. Swanson, Antonio F. Muina, Andrea B. Apolo, Gopa Iyer, Jonathan E. Rosenberg, Min Y. Teo, Dean F. Bajorin
Publikováno v:
Journal of Clinical Oncology. 41:1618-1625
PURPOSE Neoadjuvant chemotherapy (NAC) has proven survival benefits for patients with invasive urothelial carcinoma of the bladder, yet its role for upper tract urothelial carcinoma (UTUC) remains undefined. We conducted a multicenter, single-arm, ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be463b3431658eb9a0e64aa97e63162
https://doi.org/10.1200/jco.22.00763
https://doi.org/10.1200/jco.22.00763
Autor:
Young H Lee, Molly M Lee, Dinuka M De Silva, Arpita Roy, Cara E Wright, Tiffany K Wong, Rene Costello, Oluwole Olaku, Robert L Grubb, Piyush K Agarwal, Andrea B Apolo, Donald P Bottaro
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0241766 (2021)
Comprehensive characterizations of bladder cancer (BCa) have established molecular phenotype classes with distinct alterations and survival trends. Extending these studies within the tyrosine kinase (TK) family to identify disease drivers could impro
Externí odkaz:
https://doaj.org/article/5394fb87b5264fd6b4b74d104edefe1c
Autor:
Andrea B. Apolo, Gopa Iyer, Srikala S. Sridhar, Pooja Ghatalia, Daniel Girardi, Parminder Singh
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 41:39-47
Bladder cancer is an aggressive and lethal disease. Even when presenting as localized muscle-invasive disease, the 5-year survival rate is about 70%, and the recurrence rate after radical cystectomy is approximately 50%. Neoadjuvant chemotherapy (NAC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf1adddd6c95184a6fc5452b0c4d0f85
https://doi.org/10.1016/j.urolonc.2020.10.006
https://doi.org/10.1016/j.urolonc.2020.10.006